Drug targets in inflammation and immunomodulation

被引:10
作者
Buckle, DR [1 ]
Hedgecock, CJR [1 ]
机构
[1] PHARMACIA & UPJOHN INC, S-75182 UPPSALA, SWEDEN
关键词
D O I
10.1016/S1359-6446(97)01074-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Major advances in our understanding of inflammation and immunomodulation at both the biological and molecular level have opened up multiple opportunities for therapeutic intervention. Some of the more established of these approaches have now been validated clinically, but there is still a long way to go before the mainstay treatments such as steroids and the nonsteroidal anti-inflammatory drugs have significant competition. This review attempts to summarize some of the ongoing activities in this area, while recognizing that a truly comprehensive insight into many exciting research activities is not possible.
引用
收藏
页码:325 / 332
页数:8
相关论文
共 84 条
  • [1] NF-kappa B: A pivotal role in asthma and a new target for therapy
    Barnes, PJ
    Adcock, IM
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (02) : 46 - 50
  • [2] BARNETTE MS, 1994, CHALLENGES DRUG DISC, V3
  • [3] Chemokine receptors and HIV-1: An attractive pair?
    Bates, P
    [J]. CELL, 1996, 86 (01) : 1 - 3
  • [4] A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders
    Baxter, AD
    Bird, J
    Bhogal, R
    Massil, T
    Minton, KJ
    Montana, J
    Owen, DA
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (07) : 897 - 902
  • [5] BEAVO JA, 1994, MOL PHARMACOL, V46, P399
  • [6] Recent advances in matrix metalloproteinase inhibitor research
    Beckett, RP
    Davidson, AH
    Drummond, AH
    Huxley, P
    Whittaker, M
    [J]. DRUG DISCOVERY TODAY, 1996, 1 (01) : 16 - 26
  • [7] A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells
    Black, RA
    Rauch, CT
    Kozlosky, CJ
    Peschon, JJ
    Slack, JL
    Wolfson, MF
    Castner, BJ
    Stocking, KL
    Reddy, P
    Srinivasan, S
    Nelson, N
    Boiani, N
    Schooley, KA
    Gerhart, M
    Davis, R
    Fitzner, JN
    Johnson, RS
    Paxton, RJ
    March, CJ
    Cerretti, DP
    [J]. NATURE, 1997, 385 (6618) : 729 - 733
  • [8] PHARMACOLOGY OF MK-0591 (3-[1-(4-CHLOROBENZYL)-3-(T-BUTYLTHIO)-5-(QUINOLIN-2-YL-METHOXY)-INDOL-2-YL]-2,2-DIMETHYL PROPANOIC ACID), A POTENT, ORALLY ACTIVE LEUKOTRIENE BIOSYNTHESIS INHIBITOR
    BRIDEAU, C
    CHAN, C
    CHARLESON, S
    DENIS, D
    EVANS, JF
    FORDHUTCHINSON, AW
    FORTIN, R
    GILLARD, JW
    GUAY, J
    GUEVREMONT, D
    HUTCHINSON, JH
    JONES, TR
    LEGER, S
    MANCINI, JA
    MCFARLANE, CS
    PICKETT, C
    PIECHUTA, H
    PRASIT, P
    RIENDEAU, D
    ROUZER, CA
    TAGARI, P
    VICKERS, PJ
    YOUNG, RN
    ABRAHAM, WM
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1992, 70 (06) : 799 - 807
  • [9] Modulators of leukotriene biosynthesis and receptor activation
    Brooks, CDW
    Summers, JB
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (14) : 2629 - 2654
  • [10] BROWN P, 1996, 3 BATH INT S MED CHE